KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Esperion Therapeutics (ESPR) Cash from Investing Activities (2018 - 2024)

Historic Cash from Investing Activities for Esperion Therapeutics (ESPR) over the last 7 years, with Q3 2024 value amounting to -$167000.0.

  • Esperion Therapeutics' Cash from Investing Activities changed N/A to -$167000.0 in Q3 2024 from the same period last year, while for Jun 2025 it was -$167000.0, marking a year-over-year decrease of 1133.33%. This contributed to the annual value of -$317000.0 for FY2024, which is 10074.59% down from last year.
  • According to the latest figures from Q3 2024, Esperion Therapeutics' Cash from Investing Activities is -$167000.0.
  • In the past 5 years, Esperion Therapeutics' Cash from Investing Activities registered a high of $33.0 million during Q3 2022, and its lowest value of -$50.5 million during Q4 2021.
  • For the 5-year period, Esperion Therapeutics' Cash from Investing Activities averaged around $1.5 million, with its median value being $1.1 million (2020).
  • As far as peak fluctuations go, Esperion Therapeutics' Cash from Investing Activities crashed by 34198.05% in 2020, and later skyrocketed by 25000.0% in 2023.
  • Quarter analysis of 5 years shows Esperion Therapeutics' Cash from Investing Activities stood at -$12.7 million in 2020, then plummeted by 298.26% to -$50.5 million in 2021, then soared by 76.64% to -$11.8 million in 2022, then soared by 248.38% to $17.5 million in 2023, then crashed by 100.95% to -$167000.0 in 2024.
  • Its last three reported values are -$167000.0 in Q3 2024, -$77000.0 for Q2 2024, and -$73000.0 during Q1 2024.